595 related articles for article (PubMed ID: 33946594)
1. Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with
Metro G; Baglivo S; Bellezza G; Mandarano M; Gili A; Marchetti G; Toraldo M; Molica C; Reda MS; Tofanetti FR; Siggillino A; Prosperi E; Giglietti A; Di Girolamo B; Garaffa M; Marasciulo F; Minotti V; Gunnellini M; Guida A; Sassi M; Sidoni A; Roila F; Ludovini V
Genes (Basel); 2021 Apr; 12(5):. PubMed ID: 33946594
[TBL] [Abstract][Full Text] [Related]
2. Clinical and molecular characteristics of epidermal growth factor receptor exon 20 insertion mutations in non-small-cell lung cancer.
Geng D; Guo Q; Huang S; Zhang H; Guo S; Li X
Clin Transl Oncol; 2022 Feb; 24(2):379-387. PubMed ID: 34453698
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the Clinical Characteristics and Prognosis of Advanced Non-Small Cell Lung Cancer with Exon 20 Insertions.
Wang H; Xu Y; Lin J; Huang Y
Cancer Control; 2024; 31():10732748241262190. PubMed ID: 38857163
[TBL] [Abstract][Full Text] [Related]
4. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract][Full Text] [Related]
5. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study.
Yang G; Li J; Xu H; Yang Y; Yang L; Xu F; Xia B; Zhu VW; Nagasaka M; Yang Y; Li Y; Qiu W; Ying J; Ou SI; Wang Y
Lung Cancer; 2020 Jul; 145():186-194. PubMed ID: 32336530
[TBL] [Abstract][Full Text] [Related]
6. First-line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non-small cell lung cancer with EGFR exon 20 insertions: Real-world evidence from China.
Yang G; Yang Y; Liu R; Li W; Xu H; Hao X; Li J; Zhang S; Xu F; Lei S; Wang Y
Cancer Med; 2023 Jan; 12(1):335-344. PubMed ID: 35608132
[TBL] [Abstract][Full Text] [Related]
7. Comparative Clinical Outcomes Between EGFR Ex20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors.
Girard N; Minchom A; Ou SI; Gadgeel SM; Trigo J; Viteri S; Bauml JM; Londhe A; Mahadevia P; Bazhenova L
Clin Lung Cancer; 2022 Nov; 23(7):571-577. PubMed ID: 36085282
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.
Patil T; Mushtaq R; Marsh S; Azelby C; Pujara M; Davies KD; Aisner DL; Purcell WT; Schenk EL; Pacheco JM; Bunn PA; Camidge DR; Doebele RC
Clin Lung Cancer; 2020 May; 21(3):e191-e204. PubMed ID: 31859066
[TBL] [Abstract][Full Text] [Related]
9. Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors.
Lau SCM; Fares AF; Le LW; Mackay KM; Soberano S; Chan SW; Smith E; Ryan M; Tsao MS; Bradbury PA; Pal P; Shepherd FA; Liu G; Leighl NB; Sacher AG
Clin Lung Cancer; 2021 Jul; 22(4):253-259. PubMed ID: 33582070
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic exploration of uncommon EGFR exon 20 insertion mutations in advanced non-small cell lung cancer: breaking through brambles and thorns.
Bai R; Chen X; Song W; Tian H; Cui J
J Cancer Res Clin Oncol; 2022 Jan; 148(1):163-176. PubMed ID: 34698913
[TBL] [Abstract][Full Text] [Related]
11. Immune microenvironment features and efficacy of PD-1/PD-L1 blockade in non-small cell lung cancer patients with EGFR or HER2 exon 20 insertions.
Chen K; Pan G; Cheng G; Zhang F; Xu Y; Huang Z; Fan Y
Thorac Cancer; 2021 Jan; 12(2):218-226. PubMed ID: 33210451
[TBL] [Abstract][Full Text] [Related]
12. EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy.
Shah MP; Aredo JV; Padda SK; Ramchandran KJ; Wakelee HA; Das MS; Neal JW
Clin Lung Cancer; 2022 Mar; 23(2):e148-e153. PubMed ID: 34391686
[TBL] [Abstract][Full Text] [Related]
13. Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations.
Hu M; Zhong C; Wang J; Chen J; Zhou T
Front Immunol; 2024; 15():1399975. PubMed ID: 38774882
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z
Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455
[TBL] [Abstract][Full Text] [Related]
15. Real-World Clinical Outcomes for Patients with
Li K; Bosdet I; Yip S; Ho C; Laskin J; Melosky B; Wang Y; Sun S
Curr Oncol; 2023 Jul; 30(8):7099-7111. PubMed ID: 37622996
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC.
Ishii H; Azuma K; Kawahara A; Kinoshita T; Matsuo N; Naito Y; Tokito T; Yamada K; Akiba J; Hoshino T
Thorac Cancer; 2020 Apr; 11(4):950-955. PubMed ID: 32061060
[TBL] [Abstract][Full Text] [Related]
17. Poor Efficacy of Immune Checkpoint Inhibitors Plus Chemotherapy in Lung Cancer Patients with EGFR/ERBB2 Exon 20 Insertion.
Zheng Y; Fu Y; Chen Y; Li Q; Liu T; Ding Z
Curr Oncol; 2023 Nov; 30(11):9929-9939. PubMed ID: 37999141
[TBL] [Abstract][Full Text] [Related]
18. Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors.
Chen Q; Shang X; Liu N; Ma X; Han W; Wang X; Liu Y
Front Immunol; 2022; 13():931718. PubMed ID: 35990690
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of mobocertinib and standard of care in patients with NSCLC with EGFR exon 20 insertion mutations: An indirect comparison.
Ou SI; Lin HM; Hong JL; Yin Y; Jin S; Lin J; Mehta M; Zhang P; Nguyen D; Neal JW
Lung Cancer; 2023 May; 179():107186. PubMed ID: 37075617
[TBL] [Abstract][Full Text] [Related]
20. EGFR Exon 19 Deletion is Associated With Favorable Overall Survival After First-line Gefitinib Therapy in Advanced Non-Small Cell Lung Cancer Patients.
Choi YW; Jeon SY; Jeong GS; Lee HW; Jeong SH; Kang SY; Park JS; Choi JH; Koh YW; Han JH; Sheen SS
Am J Clin Oncol; 2018 Apr; 41(4):385-390. PubMed ID: 26967328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
